Zoetis (ZTS) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zoetis: Undervalued And Oversold
Zoetis, the global animal health leader, is deeply undervalued at a 19x forward P/E versus its 10-year average of 31.8x. ZTS is positioned to benefit from the secular trend of pet humanization, with 66% of revenue from companion animal products. Consensus expects 8.9% annual EPS growth and 9%-10% dividend growth, supporting a fair value estimate of $170 per share.
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis: Cheap Valuation And Attractive Product Launch Pipeline
I rate Zoetis (ZTS) a buy, citing a robust pipeline, upcoming product launches, and discounted valuation versus peers. ZTS targets new therapeutic white spaces—oncology, cardiology, and renal disease—minimizing risk and offering substantial first-mover advantages. The CKD monoclonal antibody for canine renal disease, launching in 2027, could unlock a $3–4 billion market with recurring revenue potential.
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
Zoetis (ZTS) reached $125.32 at the closing of the latest trading day, reflecting a -1.45% change compared to its last close.
Zoetis Inc. (ZTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zoetis Inc. (ZTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zoetis (ZTS) Outperforms Broader Market: What You Need to Know
Zoetis (ZTS) closed at $123.78 in the latest trading session, marking a +1.26% move from the prior day.
Zoetis Inc. (ZTS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Zoetis Inc. (ZTS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Zoetis (ZTS) Up 1.7% Since Last Earnings Report: Can It Continue?
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?
Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know
ZTS faces steep YTD losses as safety concerns hit key osteoarthritis therapies, forcing revenue cuts while new approvals aim to stabilize growth.
Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript
Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript
Zoetis: A High-Quality Compounder Now On Sale?
Zoetis (ZTS) the world's largest animal-health company, develops and manufactures medicines, vaccines, and diagnostics for both pets and livestock. The stock has come under pressure in recent months as softer clinic traffic, uneven companion-animal demand, and a narrowed full-year outlook weighed on sentiment.
